<html>
<head>
<title>Utah Legislature HB0279</title>
</head>
<body>
<div id="content">
<font face="Arial">
</font><font face="Arial" size="3">1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center><b>PRESCRIPTION NOTIFICATION AMENDMENTS</b></font><font face="Arial" size="2"></center><br/>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center>2015 GENERAL SESSION</center><br/>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center>STATE OF UTAH</center><br/>4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center></font><font face="Arial" size="3"><b>Chief Sponsor:  Brad L. Dee</b></font><font face="Arial" size="2"></center><br/>5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center></font><font face="Arial" size="3">Senate Sponsor:  </font><font face="Arial" size="2"></font><font face="Arial" size="3">____________</font><font face="Arial" size="2"></center><br/>6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <hr style="width:90%; padding: 0; border: none; border-top: thick double #333; color: #333; text-align: right" /><br/>7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>LONG TITLE</b><br/>8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>General Description:</b><br/>9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This bill amends provisions related to biosimilar products in the Pharmacy Practice Act.<br/>10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Highlighted Provisions:</b><br/>11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This bill:<br/>12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;deletes the definition of biosimilar;<br/>13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;defines interchangeable biological product;<br/>14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;requires a pharmacist to notify the prescriber when a biological product is dispensed<br/>15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if an interchangeable biological product is available;<br/>16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;establishes the methods of notifying a prescriber; and<br/>17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;amends repealer language.<br/>18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Money Appropriated in this Bill:</b><br/>19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None<br/>20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Other Special Clauses:</b><br/>21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None<br/>22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Utah Code Sections Affected:</b><br/>23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AMENDS:<br/>24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#58-17b-605.5">58-17b-605.5</a></b>, as enacted by Laws of Utah 2013, Chapter 423<br/>25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#63i-2-258">63I-2-258</a></b>, as last amended by Laws of Utah 2013, Chapter 423<br/>26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <hr style="width:90%; padding: 0; border: none; border-top: thick double #333; color: #333; text-align: right" /><br/>27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>Be it enacted by the Legislature of the state of Utah:</i><br/><hr>28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 1.  Section <b>58-17b-605.5</b><a name="58-17b-605.5"></a> is amended to read:<br/>29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>58-17b-605.5.</b>   <b>Interchangeable biological products.</b><br/>30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)  For the purposes of this section:<br/>31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)  "Biological product" [<strike>is as</strike>] <u>means the same as that term is</u> defined in 42 U.S.C.<br/>32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sec. 262[<strike>;</strike>]<u>.</u><br/>33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(b)  "biosimilar" is as defined in 42 U.S.C. Sec. 262; and</strike>]<br/>34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(c)  "interchangeable" is as defined in 42 U.S.C. Sec. 262.</strike>]<br/>35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  "Interchangeable biological product" means a biological product that the federal</u><br/>36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Food and Drug Administration:</u><br/>37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(i)  has:</u><br/>38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(A)  licensed; and</u><br/>39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(B)  determined meets the standards for interchangeability pursuant to 42 U.S.C. Sec.</u><br/>40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>262(k)(4); or</u><br/>41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(ii)  has determined is therapeutically equivalent as set forth in the latest edition of or</u><br/>42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>supplement to the federal Food and Drug Administration's Approved Drug Products with</u><br/>43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Therapeutic Equivalence Evaluations.</u><br/>44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)  A pharmacist or pharmacy intern dispensing a prescription order for a specific<br/>45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;biological product by brand or proprietary name may substitute [<strike>a biosimilar</strike>] <u>an</u><br/>46&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>interchangeable biological</u> product for the prescribed biological product only if:<br/>47&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)  the purchaser specifically requests or consents to the substitute of an<br/>48&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;interchangeable [<strike>biosimilar</strike>] <u>biological</u> product;<br/>49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(b)  the biosimilar product has been determined by the United States Food and Drug</strike><br/>50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strike>Administration to be interchangeable with the prescribed biological product;</strike>]<br/>51&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(c)</strike>] <u>(b)</u>  the interchangeable [<strike>biosimilar</strike>] <u>biological</u> product is permitted to move in<br/>52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;interstate commerce;<br/>53&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(d)</strike>] <u>(c)</u>  the pharmacist or pharmacy intern counsels the patient on the use and the<br/>54&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;expected response to the prescribed biological product, whether a substitute or not, and the<br/>55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;substitution is not otherwise prohibited by this chapter;<br/>56&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(e)</strike>] <u>(d)</u>  the prescribing practitioner has not prohibited the substitution of an<br/>57&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;interchangeable [<strike>biosimilar</strike>] <u>biological</u> product for the prescribed biological product, as<br/>58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;provided in Subsection (6); and<br/><hr>59&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(f)</strike>] <u>(e)</u>  the substitution is not otherwise prohibited by law.<br/>60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) [<strike>(a)</strike>]  Each out-of-state mail service pharmacy dispensing an interchangeable<br/>61&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>biosimilar</strike>] <u>biological</u> product as a substitute for another biological product into this state<br/>62&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall<u>:</u><br/>63&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)</u>  notify the patient of the substitution either by telephone or in writing[<strike>.</strike>]<u>; and</u><br/>64&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)  [<strike>Each out-of-state mail service pharmacy shall</strike>] comply with the requirements of<br/>65&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this chapter with respect to an interchangeable [<strike>biosimilar</strike>] <u>biological</u> product substituted for<br/>66&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;another biological product, including labeling and record keeping.<br/>67&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)  Pharmacists or pharmacy interns may not substitute without the prescriber's<br/>68&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;authorization biological product prescriptions unless the product has been determined by the<br/>69&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;United States Food and Drug Administration to be interchangeable with the prescribed<br/>70&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;biological product.<br/>71&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)  A pharmacist or pharmacy intern who dispenses a prescription with an<br/>72&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;interchangeable [<strike>biosimilar</strike>] <u>biological</u> product under this section assumes no greater liability<br/>73&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;than would be incurred had the pharmacist or pharmacy intern dispensed the prescription with<br/>74&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the biological product prescribed.<br/>75&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) (a)  If, in the opinion of the prescribing practitioner, it is in the best interest of the<br/>76&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;patient that an interchangeable [<strike>biosimilar</strike>] <u>biological</u> product not be substituted for a<br/>77&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prescribed biological product, the practitioner may prohibit a substitution either by writing<br/>78&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"dispense as written" or by signing in the appropriate space where two lines have been<br/>79&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;preprinted on a prescription order and captioned "dispense as written" or "substitution<br/>80&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;permitted."<br/>81&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) (i)  If the prescription is communicated orally by the prescribing practitioner to the<br/>82&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pharmacist or pharmacy intern, the practitioner shall direct the prohibition or substitution.<br/>83&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  The pharmacist or pharmacy intern shall make a written note of the practioner's<br/>84&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;direction by writing the name of the practitioner and the words "orally by" and the initials of<br/>85&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the pharmacist or pharmacy intern written after it.<br/>86&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7)  A pharmacist or pharmacy intern who substitutes an interchangeable [<strike>biosimilar</strike>]<br/>87&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>biological</u> product for a prescribed biological product shall communicate the substitution to the<br/>88&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;purchaser.  The interchangeable [<strike>biosimilar</strike>] <u>biological</u> product container shall be labeled with<br/>89&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the name of the interchangeable [<strike>biosimilar</strike>] <u>biological</u> product dispensed, and the pharmacist,<br/><hr>90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pharmacy intern, or pharmacy technician shall indicate on the file copy of the prescription both<br/>91&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the name of the prescribed biological product and the name of the interchangeable [<strike>biosimilar</strike>]<br/>92&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>biological</u> product dispensed in its place.<br/>93&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(8) (a)  A pharmacist or pharmacy intern who substitutes an interchangeable biosimilar</strike><br/>94&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strike>product for a prescribed biological product shall:</strike>]<br/>95&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(i)  notify the prescriber in writing, by fax, telephone, or electronic transmission of the</strike><br/>96&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strike>substitution, as soon as practicable, but not later than three business days after dispensing the</strike><br/>97&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strike>interchangeable biosimilar product in place of the prescribed biological product; and</strike>]<br/>98&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(ii)  include the name and manufacturer of the interchangeable biosimilar product</strike><br/>99&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strike>substituted.</strike>]<br/>100&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(b)  This subsection is repealed on May 15, 2015.</strike>]<br/>101&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(8)  Within a reasonable time following the dispensing of a biological product, the</u><br/>102&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>dispensing pharmacist or the pharmacist's designee shall communicate to the prescriber the</u><br/>103&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>specific product provided to the patient, including the name of the product and the</u><br/>104&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>manufacturer.  The communication shall be conveyed by making an entry in an interoperable</u><br/>105&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>electronic medical records system or through an electronic prescribing technology or a</u><br/>106&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>pharmacy record that is electronically accessible by the prescriber.  Otherwise, the pharmacist</u><br/>107&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>shall communicate the biological product dispensed to the prescriber using facsimile,</u><br/>108&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>telephone, electronic transmission, or other prevailing means, provided that communication</u><br/>109&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>shall not be required where:</u><br/>110&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  there is no FDA-approved interchangeable biological product for the product</u><br/>111&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>prescribed; or</u><br/>112&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  a refill prescription is not changed from the product dispensed on the prior filling of</u><br/>113&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>the prescription.</u><br/>114&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(9)  The board shall maintain a link on its website to the current list of all</u><br/>115&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>interchangeable biological products.</u><br/>116&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 2.  Section <b>63I-2-258</b><a name="63i-2-258"></a> is amended to read:<br/>117&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>63I-2-258.</b>   <b>Repeal dates -- Title 58.</b><br/>118&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(1)  Subsection <a href="http://le.utah.gov/UtahCode/SectionLookup.jsp?section=58-72-201&session=2015GS">58-72-201</a>(1)(b) is repealed July 1, 2014.</strike>]<br/>119&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(2)  Subsection <a href="#58-17b-605.5">58-17b-605.5</a>(8) is repealed on May 15, 2015.</strike>]<br/><br/><hr><hr style="width:90%; color: #333; text-align: right" /><br/><hr style="width:90%; color: #333; text-align: right" /><br/><br/><b>Legislative Review Note<br/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as of   1-26-15  11:14 AM</b><br/><br/><div align="right"><b>Office of Legislative Research and General Counsel</b></div>
</font>
</div>
</body>
</html>
